<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293981</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-000058</org_study_id>
    <nct_id>NCT01293981</nct_id>
  </id_info>
  <brief_title>Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF)</brief_title>
  <official_title>Radiographic and Clinical Outcomes of PureGen Osteoprogenitor Cell Allograft in Posterior Lumbar and Transforaminal Interbody Fusion Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alphatec Spine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alphatec Spine, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of PureGen Osteoprogenitor
      Cell Allograft in patients undergoing Posterior Lumbar or Transforaminal Interbody Fusion.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Product no longer on the market
  </why_stopped>
  <start_date>February 2011</start_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fusion</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of subjects with fusion at the 24 month visit</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">6</enrollment>
  <condition>Lumbar Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>Lumbar Degenerative Disc Disease</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PureGen Osteoprogenitor Cell Allograft</intervention_name>
    <description>PureGen Osteoprogenitor Cell Allograft.</description>
    <arm_group_label>Lumbar Degenerative Disc Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects diagnosed with symptomatic lumbar degenerative disc disease (DDD) at 1 or 2
        contiguous levels between L1 and S1.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with back and/or leg pain electing to receive Transforaminal Lumbar Interbody
             Fusion (TLIF)/ Posterior Lumbar Interbody Fusion (PLIF) procedure and posterior
             transpedicular stabilization with or without decompression at any level

          -  Unresponsive to conservative treatment for at least 6 months

          -  Radiographic confirmation of primary diagnosis

        Exclusion Criteria:

          -  More than 2 levels requiring lumbar interbody fusion

          -  Spondylolisthesis greater than Grade I

          -  Prior failed fusion surgery at any lumbar level(s)

          -  Local or systemic infection past or present

          -  Active systemic disease

          -  Osteoporosis, osteomalacia, or other metabolic bone disease that would significantly
             inhibit bone healing

          -  BMI greater than 40

          -  Use of other bone graft, Bone Morphogenetic Protein (BMP) or bone graft substitutes in
             addition to or in place of those products specified

          -  Use of post operative Spinal Cord Stimulator (SCS)

          -  Any condition requiring postoperative medications that inhibit fusion, such as chronic
             use of oral or injected steroids or prolonged use of non-steroidal anti-inflammatory
             drugs

          -  Known or suspected history of alcohol and/or drug abuse

          -  Involved in pending litigation or worker's compensation related to the spine

          -  Pregnant or plans to become pregnant during the course of the study

          -  Insulin-dependent diabetes mellitus

          -  Known sensitivity to device materials

          -  Life expectancy less than duration of study

          -  Any significant psychological disturbance that could impair consent process or ability
             to complete self-assessment questionnaires

          -  Undergoing chemotherapy or radiation treatment

          -  Known history of hypersensitivity or anaphylactic reaction to dimethyl sulfoxide
             (DMSO)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middleton</city>
        <state>Connecticut</state>
        <zip>06457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2011</study_first_posted>
  <last_update_submitted>January 15, 2016</last_update_submitted>
  <last_update_submitted_qc>January 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

